GlassScriptPhysician profile
Michael H Mckenzie
NPI 1538146725
$13,003.75
in general payments reported to CMS, 2019-2025
35 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,835 · 2020: $1,450 · 2021: $1,543 · 2022: $3,753 · 2023: $1,339 · 2024: $791 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,423.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,906.27 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $1,343.11 | 2019-2021 | |
| Abbott Laboratories | $1,204.72 | 2020-2024 | Proclaim, Freestyle Libre |
| Teva Pharmaceuticals USA, INC. | $959.09 | 2019-2022 | |
| Novo Nordisk INC | $773.17 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $655.74 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $545.51 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $495.63 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $436.30 | 2019-2025 | |
| Medtronic, INC. | $418.97 | 2022-2024 | Mycarelink, Mcgrath Mac, Closurefast |
| Astrazeneca Pharmaceuticals LP | $338.00 | 2019-2021 | |
| Amarin Pharma, INC. | $288.92 | 2019-2021 | |
| Allergan, INC. | $265.29 | 2020 | |
| Esperion Therapeutics, INC. | $242.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.65 | 2025 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $184.87 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Viiv Healthcare Company | $169.79 | 2025 | Apretude |
| Radius Health, INC. | $164.20 | 2019-2020 | |
| Angiodynamics, INC. | $159.61 | 2023 | Nanoknife |
| Exact Sciences Corporation | $141.85 | 2023-2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $139.99 | 2024 | Opsumit, Uptravi |
| Ironwood Pharmaceuticals, INC | $125.00 | 2019 | |
| Astellas Pharma US INC | $124.99 | 2024 | Veozah |
| Smith+Nephew, INC. | $121.87 | 2022 | |
| Novartis Pharmaceuticals Corporation | $121.82 | 2019 | |
| Merck Sharp & Dohme LLC | $114.71 | 2025 | Capvaxive |
| Kowa Pharmaceuticals America, INC. | $114.26 | 2025 | Zoryve |
| Saluda Medical Americas, INC. | $74.96 | 2025 | Evoke |
| Sanofi-Aventis U.S. LLC | $26.98 | 2021-2023 | |
| Horizon Therapeutics Plc | $19.43 | 2023 | Krystexxa |
| Seqirus USA INC | $17.37 | 2019 | |
| Hologic Sales and Service, LLC | $17.13 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.76 | 2023 | Nuzyra |
| Shield Therapeutics INC | $16.38 | 2023 | Accrufer |
| Kaleo, INC. | $15.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.